Disclosures: Leeor Hershkovich: Nothing to Disclose, Harel Dahari: Nothing to Disclose, Scott Cotler: Nothing to Disclose, Theo Heller: Nothing to Disclose, Christopher Koh: Nothing to Disclose, Jeffrey Glenn: Nothing to Disclose, Tarik Asselah: Nothing to Disclose, Saeed Hamid: Nothing to Disclose, Ohad Etzion: Nothing to Disclose 428 HIGHER SUSTAINED RESPONSE RATE AND PARTIAL CURE IN NUC EXPERIENCED PEGYLATED INTERFERON-TREATED PATIENTS COMPARED TO NUC NAÏVE PEGYLATED INTERFERON MONOTHERAPY PATIENTS Rachel Wen-Juei Jeng 1 Yu-Ting Kao 2 Yen-Chun Liu 2 Rong-Nan Chien 2 , 1 Chang Gung Medical Foundation, 2 Chang Gung Memorial Hospital, Linkou Medical Center, Taiwan Background: Our previous study showed that patients with off-Nuc clinical relapse (CR) retreated with pegylated interferon (Peg-IFN) also had a higher functional cure rate than NUC-nave Peg-IFN patients (10-year: 49.2% vs
Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease
What is N-acetyl cysteine (NAC)
Piriformospora indica cell wall extract as the best elicitor for asiaticoside production in Centella asiatica (L.) urban, evidenced by morphological, physiological and molecular analyses
